---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-26-000037"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:52:46.572228+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit Q1 net loss $189.4M, cash $598.7M; ivonescimab OS data at ASCO plenary

## Summary
- GAAP net loss $189.4M ($0.24/sh) vs $62.9M ($0.09/sh) YoY; non-GAAP net loss $116.6M ($0.15/sh).
- Cash and short-term investments $598.7M, down $114.7M from Dec 2025; cash burn funds ivonescimab trials.
- HARMONi-6 (squamous NSCLC in China) OS data to be presented at ASCO 2026 plenary as late-breaking abstract.
- HARMONi-3 squamous final PFS expected H2 2026; interim PFS cleared by iDMC, study continues blinded.
- BLA for ivonescimab in EGFR-mutated NSCLC accepted; PDUFA date Nov 14, 2026.

## SEC filing metadata
- accession: 0001599298-26-000037
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/0001599298-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/smmt-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-26-000037
- JSON: https://secwatch.observer/filing/0001599298-26-000037.json
- Plain text: https://secwatch.observer/filing/0001599298-26-000037.txt

## Key facts
- Earnings Releases
  Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On April 30, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/0001599298-26-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.